Bengaluru: In what can easily be deduced as an inclination towards Ayurvedic products, the Indian Medicines Pharmaceutical Corporation Limited (IMPCL), the public sector manufacturing unit of the Ministry of Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) has recorded a turnover of Rs 164.33 crore for the financial year 2020-21, reports Swarajya. 

It has also reported a profit of Rs 12 crore, a high profit in the company’s history. 

This growth is reflective of the fast-growing adoption of AYUSH products and services by the public in the wake of Covid-19 pandemic, the Ministry of AYUSH said. 

It is to be noted that the World Health Organisation (WHO) recently recommended its 18 Ayurvedic products for WHO-GMP/COPP certification.

What this means is that the body can start exporting its products globally. 

Currently, it is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum. It has contributed towards research and development activities and 25 new proprietary ayurvedic medicines as per the Essential Drug List (EDL).

Every government institution doing business with IMPCL has praised the company for providing steady support to various health programmes and ensuring an unbroken supply of products during the Covid-19 pandemic.